These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 9484812

  • 41. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833.
    Jaffrézou JP, Dumontet C, Derry WB, Durán G, Chen KG, Tsuchiya E, Wilson L, Jordan MA, Sikic BI.
    Oncol Res; 1995; 7(10-11):517-27. PubMed ID: 8866664
    [Abstract] [Full Text] [Related]

  • 42. Identification of betaIII- and betaIV-tubulin isotypes in cold-adapted microtubules from Atlantic cod (Gadus morhua): antibody mapping and cDNA sequencing.
    Modig C, Olsson PE, Barasoain I, de Ines C, Andreu JM, Roach MC, Ludueña RF, Wallin M.
    Cell Motil Cytoskeleton; 1999; 42(4):315-30. PubMed ID: 10223637
    [Abstract] [Full Text] [Related]

  • 43. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
    Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T.
    Biochem Pharmacol; 2001 Dec 01; 62(11):1469-80. PubMed ID: 11728383
    [Abstract] [Full Text] [Related]

  • 44. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
    Tripathi S, Srivastava G, Sharma A.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):273-279. PubMed ID: 27233604
    [Abstract] [Full Text] [Related]

  • 45. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells.
    Parekh H, Wiesen K, Simpkins H.
    Biochem Pharmacol; 1997 Feb 21; 53(4):461-70. PubMed ID: 9105396
    [Abstract] [Full Text] [Related]

  • 46. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance.
    Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB.
    J Biol Chem; 1995 Dec 29; 270(52):31269-75. PubMed ID: 8537394
    [Abstract] [Full Text] [Related]

  • 47. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
    Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T.
    Cancer Res; 1998 Aug 01; 58(15):3331-8. PubMed ID: 9699663
    [Abstract] [Full Text] [Related]

  • 48. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
    Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS.
    J Biol Chem; 1997 Jul 04; 272(27):17118-25. PubMed ID: 9202030
    [Abstract] [Full Text] [Related]

  • 49. Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis.
    Das L, Bhattacharya B, Basu G.
    BMC Res Notes; 2012 Aug 01; 5():395. PubMed ID: 22849332
    [Abstract] [Full Text] [Related]

  • 50. Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.
    Tamura D, Arao T, Nagai T, Kaneda H, Aomatsu K, Fujita Y, Matsumoto K, De Velasco MA, Kato H, Hayashi H, Yoshida S, Kimura H, Maniwa Y, Nishio W, Sakai Y, Ohbayashi C, Kotani Y, Nishimura Y, Nishio K.
    Cancer Med; 2013 Apr 01; 2(2):144-54. PubMed ID: 23634282
    [Abstract] [Full Text] [Related]

  • 51. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G, Azarenko O, Miller H, Rifkind A, LaPointe NE, Wilson L, Jordan MA.
    Cancer Chemother Pharmacol; 2017 Jul 01; 80(1):151-164. PubMed ID: 28567478
    [Abstract] [Full Text] [Related]

  • 52. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.
    Kavallaris M, Burkhart CA, Horwitz SB.
    Br J Cancer; 1999 Jun 01; 80(7):1020-5. PubMed ID: 10362110
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
    Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T.
    Oncogene; 2000 Jun 22; 19(27):3078-85. PubMed ID: 10871860
    [Abstract] [Full Text] [Related]

  • 56. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

  • 57. Cardiac glycosides induce resistance to tubulin-dependent anticancer drugs in androgen-independent human prostate cancer.
    Huang DM, Guh JH, Huang YT, Chueh SC, Wang HP, Teng CM.
    J Biomed Sci; 2002 Nov 15; 9(5):443-52. PubMed ID: 12218360
    [Abstract] [Full Text] [Related]

  • 58. Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
    Liu B, Staren E, Iwamura T, Appert H, Howard J.
    World J Gastroenterol; 2001 Dec 15; 7(6):855-9. PubMed ID: 11854916
    [Abstract] [Full Text] [Related]

  • 59. Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells.
    Lobert S, Jefferson B, Morris K.
    Cytoskeleton (Hoboken); 2011 Jun 15; 68(6):355-62. PubMed ID: 21634028
    [Abstract] [Full Text] [Related]

  • 60. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
    Zhou J, Cheng SC, Luo D, Xie Y.
    Biochem Biophys Res Commun; 2001 Feb 09; 280(5):1237-42. PubMed ID: 11162660
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.